Best of the Week
Most Popular
1.London House Prices Bubble, Debt Slavery, Crimea 2.0 - Russia Ukraine Annexation - Nadeem_Walayat
2. Gold And Silver – 2014 Coud Be A Yawner; Be Prepared For A Surprise - Michael_Noonan
3.Sheffield, Rotherham Roma Benefits Plague, Ch5 Documentary Gypsies on Benefits & Proud - Nadeem_Walayat
4.Glaring Q.E. Failure Spotted - Money Velocity Is Falling Rapidly - Jim_Willie_CB
5.Don't Miss the Boat on Big Biotech Catalysts: Keith Markey - Keith Markey
6.Gold Prices 2014: Do What Goldman Does, Not What It Says - David Zeiler
7.Bitcoin Price Strong Appreciation to Be Followed by Declines? - Mike_McAra
8.Gold Preparing to Launch as U.S. Dollar Drops to Key Support - Jason_Hamlin
9.Doctor Doom on the Fiat Money Empire Coming Financial Crisis - Andrew_McKillop
10.The Real Purpose Of QE - It’s Not Employment - Darryl_R_Schoon
Last 72 Hrs
America has Become a Police State - 19th Apr 14
Elite Herd Psychology And War By Default - 19th Apr 14
E.U. Officially Adopts the Bank Depositors Bail-In - 19th Apr 14
Goldman Sachs Is Highly Motivated To Low-Ball Gold Price - 19th Apr 14
Save MtGox - Bitcoin Important Implications of Going Down - 19th Apr 14
Stock Market SPX Topping Valuations - 19th Apr 14
Tesco Profits Panic! Back to Back £5 Off £40 Shop Voucher Promotions - 18th Apr 14
The Obama Game - Is Putin Being Lured Into a Trap? - 18th Apr 14
The Growing Threat to Capitalism - 18th Apr 14
Build Biotech Wealth on Solid Platforms - 18th Apr 14
Has Solar Power Finally Arrived? - 18th Apr 14
Bank Depositor Bail-Ins and Real Assets vs Liability-Based Assets - 18th Apr 14
10 Ways to Screw up Your Retirement - 17th Apr 14
One of Harry Dent’s Three Keys to Market Prediction is Cycles - 17th Apr 14
Obamacare Proof Stocks - 17th Apr 14
Gold, Silver And The Mining Sector: Prepare For A Severe Fall - 17th Apr 14
Hidden Australian Life Sciences Bio-tech Growth Stocks - 17th Apr 14
Disrupting Big Data Status Quo - 17th Apr 14
What the Stock Market Bears Have Been Waiting for... - 17th Apr 14
Copper Is Pathological and Suffers from SAD, but It Has Value - 17th Apr 14
Old World Order New World Order, Chaos And Change - 17th Apr 14
Even The US Government Will Abandon the U.S. Dollar - 17th Apr 14
Gold - Coming Super Bubble - 17th Apr 14
Glaring Q.E. Failure Spotted - Money Velocity Is Falling Rapidly - 16th Apr 14
High-Frequency Insider Trading - 16th Apr 14
Gold Prices 2014: Do What Goldman Does, Not What It Says - 16th Apr 14
These CEOs Will Make Investors Rich - 16th Apr 14
Climate Change, Central Banking And The Faustian Bargain - 16th Apr 14
Every Central Bank for Itself - 16th Apr 14
Social Security, U.S. Treasury Stealing Every Last Penny From Americans - 16th Apr 14
Ukraine Falling to Economic Warfare and Its Own Missteps - 16th Apr 14
Silver and Gold Miners Still Disappoint - 16th Apr 14
Silver, Gold, and What Could Go Wrong - 15th Apr 14
How I Intend to Survive the Meltdown of America - 15th Apr 14
France Wakes Up To The Multicultural Multi-Threat - 15th Apr 14
The Real Purpose Of QE - It’s Not Employment - 15th Apr 14
Peak Coal - 15th Apr 14
Flash Crash, Rigged Markets - What’s the Frequency Zenith? - 15th Apr 14
Forecasting U.S. GDP Growth: A Look at WSJ Economists’ Collective Crystal Ball - 15th Apr 14
Stock Market - Is Something Nasty About to Happen? - 15th Apr 14
How to Trade Your Way To Freedom - 15th Apr 14
Understanding (and Ignoring) the Media Bandwagon Against Gold - 15th Apr 14
When Stock Market Bubble Crashes, Take Refuge in Gold Stocks - 15th Apr 14

Free Instant Analysis

Free Instant Technical Analysis


Market Oracle FREE Newsletter

Biotech Stocks to Buy Now

Companies / BioTech Nov 15, 2012 - 09:35 AM GMT

By: Money_Morning

Companies

Best Financial Markets Analysis ArticleDon Miller writes: If you're looking to hit a home run over the next 12 months, your best bet for stocks to buy now is biotechnology companies - especially those focused on cancer research.

Here's why: biotech stocks have been in a stealth bull market in 2012.


In fact, the values of the 230 publicly-traded biotech companies tracked by the BioWorld Stock Report have jumped by an average 38% year-to-date.

The third quarter was especially hot. The Nasdaq Biotechnology Index rose 10% over that time frame and is up a healthy 37% this year.

And, nothing is hotter than companies focused on the battle against cancer.

Take Medivation Inc. (Nasdaq: MDVN), for example. This California-based biotech has jumped from $23 to $46 a share, largely on the approval of Xtandi, its novel prostate cancer drug.

Thousands of other experimental drugs are going through various stages of clinical trials, and the largest category in the pipeline is cancer drugs. With that in mind, it's safe to say that if you're looking for a stock with big upside potential, cancer-driven biotech stocks should be high on your list. Biotech Stocks: Cancer Research is Paying Off

A cancer diagnosis was once a death sentence -- especially if you were diagnosed with the disease in its late stages.

But, both government and industry have spent vast sums in the last decade researching how cancers develop and spread.

And now all that investment is starting to pay off -- recent clinical trials and treatment breakthroughs show real promise.

The newest cancer research focuses on three fronts.

•Finding ways to boost the ability of the body's own immune system to recognize and kill malignant cells.
•Identifying unique characteristics of cancer cells and aiming drugs to destroy only those cells - as opposed to traditional chemotherapy, which kills healthy cells, too.
•Blocking the pathways used by cancer cells to spread throughout the body and killing the trapped cells before they escape and multiply.
These revolutionary new therapies have given patients renewed hope -- and investors good reasons to bid up shares of biotech companies that specialize in cancer cures.

Three Phases of Drug Testing
The value of a company that's working on cancer cures hinges on how its drugs progress through clinical trials.

The Food and Drug Administration (FDA) requires drug makers to navigate a three-stage testing process to prove a drug's safety and effectiveness.

New drugs are first tested on humans in Phase One trials to determine whether a drug is effective and if it has serious side effects.

Phase Two testing treats a specific illness in a larger group of patients at a predetermined dose level and measures how patients tolerate it.

Phase Three trials compare the benefits of the drug against existing treatments.

If the drug ultimately proves both effective and safe, the results are submitted to the FDA for approval.

Clinical trials are everything, since 95% of all new drugs never make it through clinical trials.

But as a drug successfully completes each trial, the odds of success rise. And analysts start to boost their values -- often by exponential amounts.

Still, almost anything can happen before a drug gets final regulatory approval.

"These are inherently risky assets," said analyst Geoffrey Porges of Bernstein Research.

Three Biotech Stocks to Buy Now
For investors, that presents both challenge and opportunity.

The failure of a single clinical trial can send both the company and its investors into a tailspin. Conversely, if a drug succeeds, a small company could suddenly have the potential to double in price overnight.

By focusing on biotech stocks with drug candidates headed into late stage clinical trials you can vastly increase your odds of finding a winner to buy now.

Here are three cancer-focused biotech stocks that experts feel are worth a look:

•Exelixis Inc. (Nasdaq: EXEL) is developing Cabozantinib, an inhibitor of tumor growth in the development and progression of various cancers. The drug is in Phase III trials for the treatment of thyroid cancer and also in clinical programs focused on the treatment of prostate, ovarian, breast cancer and melanoma. In addition, Exelixis is collaborating on additional therapies with heavy hitters like Bristol-Myers Squibb Co. (NYSE: BMY), Sanofi SA (ADR NYSE: SNY) and GlaxoSmithKline plc (ADR NYSE: GSK).

•ARIAD Pharmaceuticals, Inc.'s (Nasdaq: ARIA) Ridaforolimus is being studied in multiple clinical trials in patients with metastatic sarcomas, breast cancer, endometrial cancer, prostate cancer and lung cancer. The company has collaboration and license agreements with deep-pocketed Merck & Co. Inc. (NYSE: MRK) for the development, manufacture and commercialization of ridaforolimus and licenses to develop and commercialize stents and other medical devices to deliver the drug.
•And in June, the FDA approved Carfilzomib, the Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) drug for multiple myeloma. According to analysts' estimates compiled by Bloomberg News, the drug could ring up annual sales of $523 million by 2016 -- more than doubling last year's revenues. Onyx is also involved in a partnership with Bayer AG (ADR PINK: BAYRY) with drugs that treat kidney and liver cancers.

As for a fourth, Private Briefing Editor Bill Patalon has discovered a biotech stock with a large, sudden and concentrated block of insider buying. In fact, these insiders just spent $353,000 on the purchase of nearly 215,000 shares of their company's stock.

According to Bill, this company is so strong its shares could jump by 295%.

To learn more about this company click here.

Source :http://moneymorning.com/2012/11/15/three-biotech-stocks-to-buy-now/

Money Morning/The Money Map Report

©2012 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email: customerservice@moneymorning.com

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Money Morning Archive

© 2005-2014 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

Free Report - Financial Markets 2014